Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Investor Villiage message board.
Best MB if you own ZIOP
Hate to admit it but I don't know what the IV board is. Can you fill me in.
I'm a long time believer in Ziop. And noticed it is up a lot today.
Thinking maybe they made a presentation at conference???
Many thanx in advance
Criz
Good stuff….thank you.
Back in under 8 stock has been cut in half since its 52 week high.
Re: ZIOP vs KITE ?
ZIOP-XON-MD Anderson-National Cancer Institute-Merck Germany are the only consortium with the Rheo Switch available to them - gene therapy that is inert in the body turned on daily with an oral ligand...the recent KITE patient death fear highlights the importance of this versus having a gene therapy that is always on that could go haywire...as Medical Tech Stock Letter...(# 1 rated) recently wrote - ZIOP should have gone up in a rational market on that news....I have owned KITE and JUNO and ZIOP and BLUE.....Now I own ZIOP and XON....FDA/NCI will use inert turn on as standard of care not always on.
Med Tech -Two Phase I/II Data Readouts & Partnership (?) By The End of 2015; Loeb Initiates ZIOP Position
A wild rumor that a patient had died in a KITE CAR-T trial circulated Wall Street last week and all the CAR-T stocks, including ZIOP, sold off in sympathy. KITE held a conference call to clear up the mess this week and said that the patient died from natural causes, not the CAR-T therapy. Regardless, the patient death boldly illustrates, in our view, why ZIOP’s second-generation gene therapy is the future of CAR-T. ZIOP’s RheoSwitch provides a significant additional safety factor with a turnoff switch which is simply activated by taking a pill. In our view, in a more rational market environment, ZIOP’s stock should have went up on KITE’s problem as they have the simple and elegant solution to manage CAR-T patient safety via RheoSwitch.
ZIOP and their partner Intrexon have both released their Q2 results. Two important pieces of information related to their recent partnership with Merck Serono were revealed. The collaboration’s first two CAR-T targets of interest were recently selected, and Intrexon and ZIOP have started R&D efforts on these programs. The specific targets were not disclosed for competitive reasons, but we were informed that they were unique and do not target CD-19 which is what KITE, JUNO et.al. are all targeting with their first generation CAR-T technologies. The Q2 release also showed that on July 31 ZIOP received $57.5 million from Intrexon related to the upfront payment from Merck Serono deal.
Two Phase I/II Data Readouts & Partnership (?) By The End of 2015; Loeb Initiates ZIOP Position
In April 2015, ZIOP started a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy in patients with locally advanced or metastatic breast cancer. In May 2015, the Company started a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer. Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. We expect initial results from both trials will be presented at scientific meetings prior to the end of the year. In addition, we expect ZIOP to announce at least one additional partnership in H2:15. Our confidence in the value of RheoSwitch to ZIOP’s 2 -gen gene therapy platform continues to grow as we expect additional deaths to be reported in 1 gen CAR-T trials due to the variability in patient response that cause aggressive and potentially fatal Grade 4 adverse events like tumor syndrome (TLS). In our view, safety concerns will continue to grow in the first generation gene therapy world as more patients are enrolled and updates are reported on. Each safety problem with the 1 gen is an opportunity for ZIOP’s proprietary 2 gen platform to shine, as in our view the RheoSwitch technology is a game changer for ZIOP. Recently, prominent hedge fund investor Third Point filed a 13F position by purchasing almost 2 million shares
http://www.investorvillage.com/smbd.asp?mb=16353&mn=26070&pt=msg&mid=15235847
Finally closed above $13 that seems to have been resistance, next stop $15?
Thanks….good volume today sold a few more at 13.85 still have a nice position there are rumors of news next week but who knows. XON doing well also.
ZIOP over 13 with decent volume thanks to Bill Miller's recommendation on CNBC yesterday.
101 Reasons To Own Ziopharm Oncology (ZIOP)
This 101 Reasons list has been compiled to bring investors' attention to a particular company in the immuno-oncology space: Ziopharm Oncology and it trades on the Nasdaq under the ticker symbol: ZIOP. We believe that when investors, both current and future, read through this list, they will come to appreciate the opportunity that this company represents.
http://seekingalpha.com/instablog/6566781-options2wealth/4175505-101-reasons-to-own-ziopharm-oncology-ziop
Why does short interest keep climbing? (LINK)
Why Does ZIOP Short Interest Keep Climbing?
Had to be that Lewis was out and Cooper was in. No other reason at this point. Jmho
Had to be that Lewis was out and Cooper was in. No other reason at this point. Jmho
We haven't learned why the company canceled two important presentations last month yet? Still going side lines.....
Time for a latte?
ZIOP still going with good volume…..sold just a few here at 11.85. Holding a position long term.
OMg, girlfriend. So happy, boom boom ZIOP
kABOOM! ZIOP a house of fire!
Hit $10.50 :D ZIOP
You could use the sleep ms sleeping beauty :p
Wake me up if hit $ 11 :p
Almost buy $10k worth, guts say nahh ~ wheuw
Looks like ZIOP needs a tampooon today
$ZIOP recent news/filings
bullish
## source: finance.yahoo.com
Mon, 08 Jun 2015 16:43:30 GMT ~ ZIOPHARM ONCOLOGY INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhi
read full: http://biz.yahoo.com/e/150608/ziop8-k_a.html
*********************************************************
Fri, 05 Jun 2015 12:44:12 GMT ~ Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares
[at noodls] - GERMANTOWN, Md., June 5, 2015 /PRNewswire/ -- Intrexon Corporation ('Intrexon') (NYSE: XON), a leader in synthetic biology, today announced that it has determined the final distribution ratio relating ...
read full: http://www.noodls.com/view/992CD7EF8E4C243C24607989AC2EC87C30281FB0
*********************************************************
Fri, 05 Jun 2015 12:00:00 GMT ~ Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares
[PR Newswire] - GERMANTOWN, Md., June 5, 2015 /PRNewswire/ -- Intrexon Corporation ("Intrexon") (XON), a leader in synthetic biology, today announced that it has determined the final distribution ratio relating to its previously announced distribution of all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. ("ZIOPHARM") (ZIOP) common stock on or about June 12, 2015, the distribution date, as a pro rata dividend on shares of Intrexon common stock, and on warrants to purchase shares of Intrexon common stock ("Warrants"), outstanding on June 4, 2015, the record date. Based on the number of Intrexon shares outstanding and shares deliverable under Warrants as of the record date, holders of Intrexon common stock will receive 0.162203 shares of ZIOPHARM common stock in the distribution with respect to each outstanding share of Intrexon common stock they own at the close of business on the record date, and holders of Warrants will receive 0.162203 shares of ZIOPHARM common stock in the distribution with respect to each share of Intrexon common stock deliverable under the Warrants they hold at the close of business on the record date.
read full: http://finance.yahoo.com/news/intrexon-announces-distribution-ratio-distribution-120000752.html
*********************************************************
Tue, 02 Jun 2015 11:01:49 GMT ~ ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
read full: http://biz.yahoo.com/e/150602/ziop8-k.html
*********************************************************
Tue, 02 Jun 2015 11:00:00 GMT ~ ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer
[GlobeNewswire] - BOSTON -- ZIOPHARM Oncology, Inc. , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that Caesar J. Belbel, Executive Vice President, ...
read full: http://finance.yahoo.com/news/ziopharm-announces-caesar-j-belbel-110000203.html
*********************************************************
$ZIOP charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ZIOP company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ZIOP/company-info
Ticker: $ZIOP
OTC Market Place: Not Available
CIK code: 0001107421
Company name: ZIOPHARM Oncology, Inc.
Company website: http://www.ziopharm.com
Incorporated In: DE, USA
$ZIOP share structure
## source: otcmarkets.com
Market Value: $221,106,456 a/o Jun 09, 2015
Shares Outstanding: 21,848,464 a/o Mar 12, 2009
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$ZIOP extra dd links
Company name: ZIOPHARM Oncology, Inc.
Company website: http://www.ziopharm.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZIOP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZIOP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZIOP+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/news - http://finance.yahoo.com/q/h?s=ZIOP+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZIOP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZIOP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZIOP
DTCC (dtcc.com): http://search2.dtcc.com/?q=ZIOPHARM+Oncology%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ZIOPHARM+Oncology%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ZIOPHARM+Oncology%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ziopharm.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ziopharm.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ziopharm.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZIOP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001107421&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZIOP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZIOP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZIOP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZIOP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZIOP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZIOP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZIOP+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZIOP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZIOP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZIOP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZIOP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZIOP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZIOP/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZIOP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZIOP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZIOP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZIOP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZIOP
$ZIOP DD Notes ~ http://www.ddnotesmaker.com/ZIOP
Form 4 filed for distribution of the dividend as well for XON. Now we may begin to hear some news pertaining to ZIOP itself.
Form 4 filed for distribution of the dividend as well for XON. Now we may begin to hear some news pertaining to ZIOP itself.
Lol I heard that..no problem bud
Thanks. Since I started night shift I'm lost when it comes to the date, haha.
Should have bought more, I told you :p
When is the 12th?
Is the record date was the 4th with shares delivered on the 12th.
Weeeeeeee,,, lol
Maybe XON shorts buying ZIOP for tomorrow's dividend.
les forget about it and come back check after a month, lol ~ ZIOP
ZIOP les goooooooooo
Followers
|
82
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1228
|
Created
|
08/08/06
|
Type
|
Free
|
Moderators |
http://www.ziopharm.com/
http://finance.yahoo.com/q/h?s=ZIOP
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidate families that are related to cancer therapeutics that are already on the market or in development. The company�s product candidates include ZIO-101, ZIO-201, and ZIO-301, which are in phase I and/or II studies. ZIO-101, organic arsenic is in a phase I/II trial in patients with advanced myeloma, as well as a phase I trial in advanced cancers; ZIO-201, stabilized isophosphoramide mustard is in a phase I/II trial in patients with advanced sarcoma, as well as in a phase I trials in advanced cancers; and ZIO-301, an anti-cancer agent that targets mitosis like the taxanes is in a phase I trial. ZIOPHARM was founded in 2003 and is based in New York, New York.
>
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |